Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $91.19: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend.
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company developing IMCIVREE (setmelanotide) as a precision medicine for rare MC4R pathway diseases including BBS and POMC/LEPR deficiencies. IMCIVREE is approved in the US, EU/UK, and Canada; the company... Read more
Sell if holding. Engine safety override at $91.19: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 53. Score 5.9/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news boost earnings 0.70, news boost analyst 0.80, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Rhythm Pharmaceuticals, Inc.
Latest news
- NEWS Why Is Rhythm Pharma Stock Jumping Today? — benzinga Jun 15, 2026 positive
- NEWS Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155 — benzinga Jun 15, 2026 positive
- NEWS Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction — benzinga Jun 15, 2026 positive
- NEWS Rhythm Pharmaceuticals To Present Interim Phase 2 Setmelanotide Data In Prader-Willi Syndrome On June 13 At 9:00 a.m. ET — benzinga Jun 12, 2026 positive
- NEWS Rhythm Pharmaceuticals Announces Publication Of An Evidence-Based, Consensus-Driven Diagnostic Algorithm For Bardet-Bied — benzinga May 28, 2026 positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductIMCIVREE10-K Item 1A: 'Our operations to date have been primarily focused on developing and commercializing IMCIVREE (setmelanotide)'
Material Events(8-K, last 90d)
- 2026-04-03Item 5.02LOWRhythm Pharmaceuticals elected Kimberly J. Popovits to Board effective April 1, 2026; simultaneously Edward T. Mathers resigned from the Board (no disagreement cited). Routine board composition change.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $91.19: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 53. Prior stop was $84.81. Score 5.9/10, moderate confidence.
Take-profit target: $124.38 (+36.4% upside). Prior stop was $84.81. Stop-loss: $84.81.
Concentration risk — Product: IMCIVREE; Quality below floor (3.5 < 4.0).
Rhythm Pharmaceuticals, Inc. trades at a P/E of N/A (forward -111.3). TrendMatrix value score: 5.4/10. Verdict: Sell.
22 analysts cover RYTM with a consensus score of 4.3/5. Average price target: $138.
What does Rhythm Pharmaceuticals, Inc. do?Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company developing IMCIVREE (setmelanotide) as a...
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company developing IMCIVREE (setmelanotide) as a precision medicine for rare MC4R pathway diseases including BBS and POMC/LEPR deficiencies. IMCIVREE is approved in the US, EU/UK, and Canada; the company generated ~$422.5M cumulative revenue from product sales and had 414 employees as of February 2026.